Nuvation Bio Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING4
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO33%
Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.3 months). See all sponsors →
Open Nuvation Bio Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| AB-106 NCT04395677 |
P2 | Active, not recruiting | Non Small Cell Lung Cancer | 173 | 2024-06-07 (+20 mo) |
| TRUST-II NCT04919811 |
P2 | Active, not recruiting | Non Small Cell Lung Cancer | 217 | 2025-06-11 |
| NUV-1511 NCT06334432 |
P1/2 | Active, not recruiting | Advanced Solid Tumor; HER2-negative Breast Cancer | 466 | 2027-03 |
| SIGMA NCT05303519 |
P3 | Recruiting | Glioma; Astrocytoma, Grade IV | 365 | 2028-12-01 (+35 mo) |
| Taletrectinib NCT06564324 |
P3 | Recruiting | Non Small Cell Lung Cancer | 194 | 2029-01 |
| Safusidenib NCT07712757 |
P3 | Not yet recruiting | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation; Astrocytoma IDH Mutant Grade 2 | 140 | 2029-05 |
| Taletrectinib NCT07154706 |
P3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 180 | 2030-08-30 |
| Safusidenib NCT07703436 |
P2 | Recruiting | Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma | 40 | 2030-09 |